Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Operating Income: 2023-2025

Historic Operating Income for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$10.0 million.

  • Mereo BioPharma Group's Operating Income fell 6.85% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.0 million, marking a year-over-year decrease of 19.83%. This contributed to the annual value of -$47.4 million for FY2024, which is 66.68% down from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma Group's Operating Income is -$10.0 million, which was up 4.61% from -$10.5 million recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma Group's Operating Income peaked at -$811,000 during Q2 2023, and registered a low of -$15.3 million during Q4 2024.
  • In the last 3 years, Mereo BioPharma Group's Operating Income had a median value of -$10.0 million in 2025 and averaged -$9.8 million.
  • In the last 5 years, Mereo BioPharma Group's Operating Income slumped by 1,480.02% in 2024 and then climbed by 18.07% in 2025.
  • Quarterly analysis of 3 years shows Mereo BioPharma Group's Operating Income stood at -$7.1 million in 2023, then slumped by 114.30% to -$15.3 million in 2024, then declined by 6.85% to -$10.0 million in 2025.
  • Its Operating Income was -$10.0 million in Q3 2025, compared to -$10.5 million in Q2 2025 and -$11.2 million in Q1 2025.